Preprint
Case Report

This version is not peer-reviewed.

Cutaneous Toxicity and Baseline Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Case Series

Submitted:

13 November 2026

Posted:

16 November 2026

You are already at the latest version

Abstract
Background and Clinical Significance: Cutaneous toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and may impair quality of life and adherence in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR), derived from a routine blood count, is an inexpensive inflammatory marker associated with prognosis in this setting, but its relationship with TKI-induced cutaneous toxicity is largely unexplored. The primary objective of this exploratory case series was to describe the frequency, timing and clinical pattern of cutaneous toxicity during the first six months of TKI therapy. As a secondary, hypothesis-generating aim, we explored whether baseline NLR differed between patients who developed cutaneous toxicity and those who did not. Case Presentation: We retrospectively reviewed ten patients with EGFR-mutated NSCLC treated with erlotinib, afatinib or osimertinib at a single Spanish regional hospital (2023–2025). Median age was 70 years (IQR 61.75–77.50); (60%) were women, (80%) had adenocarcinoma, exon 19 deletion was the most frequent alteration (60%), and (70%) received osimertinib. Cutaneous toxicity (CTCAE v5.0) occurred in five patients at three months and seven at six months, mostly grade 1; acneiform eruption predominated early and paronychia later. Median baseline NLR was numerically lower in patients with toxicity at six months (1.69 vs 2.75; p = 0.305), with no relevant difference at three months. Conclusions: In this small, single-centre, exploratory case series, cutaneous toxicity was common during the first six months of EGFR tyrosine kinase inhibitor therapy. Although patients who developed toxicity by six months had a numerically lower baseline NLR, this difference was not statistically significant and should be interpreted only as hypothesis-generating.
Keywords: 
;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.